Navigation Links
Ambit Biosciences Provides Regulatory Update Following FDA Meeting Regarding Quizartinib (AC220)
Date:12/3/2013

DA Update Conference Call" and reference conference passcode 75822572.  If you are unable to listen to the live webcast, a teleconference replay will be available through Wednesday, December 11, 2013.  Interested parties can access the replay by dialing 888-286-8010 and entering the conference passcode 13352784.

The conference call webcast is accessible through the "Investors & Media" section of the Ambit website at http://www.ambitbio.com.  An online replay will be available following the initial broadcast until Thursday, December 19, 2013.  Please visit Ambit's website several minutes prior to the start of the broadcast to ensure adequate time for any software download that may be necessary.

About Ambit BiosciencesAmbit is a biopharmaceutical company focused on the discovery, development and commercialization of drugs to treat unmet medical needs in oncology, autoimmune and inflammatory diseases by inhibiting kinases that are important drivers for those diseases. Ambit's lead drug candidate, quizartinib (AC220), is a once-daily, orally-administered potent and selective, inhibitor of FMS-like tyrosine kinase-3 (FLT3) and is currently under clinical development in patients with relapsed/refractory AML and in newly diagnosed AML patients in combination with chemotherapy as well as maintenance following a hematopoietic stem cell transplantation (HSCT). In addition to quizartinib, Ambit's clinical pipeline includes AC410, an oral JAK2 inhibitor, and CEP-32496, a BRAF inhibitor licensed to Teva Pharmaceutical Industries Ltd. Ambit's preclinical portfolio includes a proprietary CSF1R inhibitor program.

Forward-Looking StatementsStatements contained in this press release regarding matters that are not historical facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, including statements associated with Ambit's expectations re
'/>"/>

SOURCE Ambit Biosciences
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Ambit Biosciences to Announce Third Quarter 2013 Financial and Operating Results and Conference Call
2. Ambit Biosciences Corporation Announces Second Quarter 2013 Operational Results
3. Ambit Biosciences to Announce Second Quarter 2013 Operational Results and Conference Call
4. Ambit Biosciences Announces Presentations of Data from Clinical Investigations of Quizartinib at the Annual Meeting of the American Society of Clinical Oncology
5. Lo studio pubblicato su European Radiology esalta ulteriormente lutilizzo della tomosintesi al seno di Hologic nellambito dello screening del cancro con utilizzo della doppia lettura
6. Ambit Biosciences Appoints David Parkinson, M.D., to Board of Directors
7. Astellas and Ambit to End Collaboration for Joint Development and Commercialization of FLT3 Kinase Inhibitors
8. Ambit and Astellas Announce Presentation of Results from Phase 2 ACE Study of Quizartinib in Patients with Relapsed or Refractory Acute Myeloid Leukemia (AML) at the 54th Annual Meeting of the American Society of Hematology
9. Ambit Biosciences Completes $50 Million Financing to Advance Lead Drug Candidate in Acute Myeloid Leukemia
10. Ambit Biosciences and Teva Announce Clearance of an Investigational New Drug (IND) Application for CEP-32496, A Novel BRAF(V600E) Inhibitor
11. Neodyne Biosciences Announces Issuance of U.S. Patent for Devices and Methods for Dressing Applicators
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/28/2015)... , April 28, 2015 /CNW/ - The group representing the ... drug tragedy left a two-hour meeting with Health Canada ... March 6th, Health Canada announced a $180 million support ... than six weeks after the Health Canada announcement and ... fully support the victims, the group representing ...
(Date:4/28/2015)... Israel , April 28, 2015 ... in its sixth funding cycle for U.S.- Israel ... and Energy Efficiency. To be considered, a project ... between a company and a university/research institution (one from the ... proposal should have significant commercial potential and the project outcome ...
(Date:4/27/2015)... Intarcia Therapeutics, Inc. today announced the closing of ... conversion option at a $5.5 billion Company valuation. Plans ... of additional head-to-head comparative and switch studies of ITCA ... therapies. In addition, proceeds from the financing will fund ... 650 in the United States , ...
Breaking Medicine Technology:Thalidomide Victims Gravely Concerned by Health Canada's Silence 2Opportunities for Funding U.S.-Israel Cooperation for Renewable Energy and Efficiency 2Intarcia Therapeutics Closes Novel $225 Million Synthetic Royalty Financing With Equity Conversion Option At $5.5 Billion Valuation 2Intarcia Therapeutics Closes Novel $225 Million Synthetic Royalty Financing With Equity Conversion Option At $5.5 Billion Valuation 3
... , , PITTSBURGH, Jan. 11 ... global, private High-Definition broadcasting network, has engineered a ... for world-renowned pharmaceutical and medical device companies. ... Novartis, Shire, Schering-Plough, Bristol-Myers Squib, Cardiovascular Research Foundation ...
... Maine, Jan. 11 IDEXX Laboratories, Inc. (Nasdaq: ... of 2,000 Catalyst Dx® chemistry analyzers in 2009, bringing ... in the first quarter of 2008, is a next ... integrated suite of analyzers and significantly expands the range ...
Cached Medicine Technology:VELOCITY Broadcasting Injects ROI into Pharmaceutical Sector by Engaging Medical Professionals with Experiential High-Definition Broadcast Events 2VELOCITY Broadcasting Injects ROI into Pharmaceutical Sector by Engaging Medical Professionals with Experiential High-Definition Broadcast Events 3IDEXX Laboratories Announces Catalyst Dx(R) Placement Total for 2009 and Installed Base of SmartService(TM) Customers 2
(Date:4/28/2015)... It’s not all about the law at the ... a civil litigation and plaintiff’s personal injury lawyer that has ... networks, it’s also about giving back to the community. ... Hutchinson Cancer Research Center Innovator’s Network. , “I believe there ... and lawyers can and do good community-focused work in their ...
(Date:4/28/2015)... April 28, 2015 Wimbledon Health ... provides vascular, electrocardiogram, echocardiogram, and NCV testing, has ... testing to help podiatrists diagnose peripheral arterial disease ... diagnose PAD without the aid of vascular testing,” ... Officer at Wimbledon Health Partners. “Diminished peripheral ...
(Date:4/28/2015)... April 28, 2015 “ Gwee ” ... Tech Report, which features the latest and coolest technology ... and special reporter for NewsWatch, conducted the review and ... iPad case. , As much as everyone loves their ... screen. Aside from looking at them, it's even more ...
(Date:4/28/2015)... Henderson, NV (PRWEB) April 28, 2015 ... University's Center for Ethics (June 27, 2014), prescription ... the world. Medical Science is becoming increasingly aware of ... on the market, such as chemotherapy drugs to treat ... bacteria that are quickly evolving to become increasingly resistant ...
(Date:4/28/2015)... PREVENT Life Safety, Inc., America’s premier ... of their Southern California offices from Orange, California to ... Unit I (letter I), Rancho Cucamonga, CA, 91730, is ... by the significant growth the company has realized in ... continue to provide superior life safety services, including fire ...
Breaking Medicine News(10 mins):Health News:Seattle Attorney Paul Schneiderman Helping to Combat Cancer 2Health News:Podiatrists Affiliate with Wimbledon Health Partners to Diagnose Peripheral Arterial Disease 2Health News:The Most Innovative iPad Case was Featured on NewsWatch Television 2Health News:Trivedi Science™ Announces the Beginning of Their Science Research to Create Highly Effective Pharmaceutical Drugs with Minimal Side Effects 2Health News:Trivedi Science™ Announces the Beginning of Their Science Research to Create Highly Effective Pharmaceutical Drugs with Minimal Side Effects 3Health News:Trivedi Science™ Announces the Beginning of Their Science Research to Create Highly Effective Pharmaceutical Drugs with Minimal Side Effects 4Health News:PREVENT Life Safety Moves to New Office in Rancho Cucamonga 2
... 15, 2010) -- Next week the city of Philadelphia ... Association of Physicists in Medicine (AAPM), the premier organization ... encompassing physics principles and applications in medicine and biology. ... meeting are focused on patient safety -- tailoring therapy ...
... as soldiers in 86 countries across the globe, almost ... how these children adjust after they return to their ... the characteristics of the communities to which the children ... former child soldiers from Sierra Leone who lived in ...
... Barcelona, Spain Today during the 88th General Session ... in Barcelona, Spain, presenting author S. Pradhani, University of ... Acinar Cells Regenerate Functional Glandular Structures in Modified Hydrogels." ... an ECM modified hyaluronic acid (HA) based hydrogel culture ...
... CHAPEL HILL Dozens of UNC researchers are heading ... AIDS conference this week. The International AIDS Society ... to discuss progress and chart a course for stemming ... Bill Clinton will address an estimated 25,000 attendees at ...
... By Karen Pallarito HealthDay Reporter , ... readmitted within 30 days of a hospital stay, it ... and wasteful spending on the hospital,s part. ... Cleveland Clinic researchers challenge that conventional wisdom. Their calculations ...
... has selected five physicians as recipients of two ... the Junior Faculty Career Research Training Award and ... Award. Winners were selected by ASTRO,s Research Evaluation ... Award is awarded to stimulate interest in radiation ...
Cached Medicine News:Health News:Patient safety highlights American Association of Physicists in Medicine 2Health News:Patient safety highlights American Association of Physicists in Medicine 3Health News:Patient safety highlights American Association of Physicists in Medicine 4Health News:Patient safety highlights American Association of Physicists in Medicine 5Health News:Patient safety highlights American Association of Physicists in Medicine 6Health News:Patient safety highlights American Association of Physicists in Medicine 7Health News:Patient safety highlights American Association of Physicists in Medicine 8Health News:Patient safety highlights American Association of Physicists in Medicine 9Health News:Patient safety highlights American Association of Physicists in Medicine 10Health News:Patient safety highlights American Association of Physicists in Medicine 11Health News:Patient safety highlights American Association of Physicists in Medicine 12Health News:Patient safety highlights American Association of Physicists in Medicine 13Health News:Patient safety highlights American Association of Physicists in Medicine 14Health News:Patient safety highlights American Association of Physicists in Medicine 15Health News:Patient safety highlights American Association of Physicists in Medicine 16Health News:Studies explore effects of war on former child soldiers 2Health News:Studies explore effects of war on former child soldiers 3Health News:Studies explore effects of war on former child soldiers 4Health News:New research explores relief for xerostomia cancer patients 2Health News:International AIDS conference features UNC work 2Health News:High Readmission Rates May Not Mean Worse Hospital Care 2Health News:High Readmission Rates May Not Mean Worse Hospital Care 3Health News:5 awarded ASTRO research grants 2
... 233 is an assayed quality ... the measurements of total hemoglobin ... instrumentation. It is available in ... analyzer performance at varying points ...
... is an assayed quality control material for blood ... four (4) levels for monitoring analyzer performance at ... be used on multiple test analyzers (such as ... 600). QC623 is also for use on ITC ...
... an assayed quality control material used ... gas, electrolyte, metabolite, and CO-Oximeter instrumentation. ... makes it the ideal choice for ... available in three (3) levels for ...
QC 123 is an assayed quality control material for blood gas instrumentation. It is available in three (3) levels for monitoring analyzer performance at varying points within the clinical range....
Medicine Products: